SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that its Board of Directors has elected Paulo F. Costa as Chairman of the Board, effective immediately.
Mr. Costa was formerly President and Chief Executive Officer of Novartis U.S. Corporation, where he held several other executive positions, including Head of the Americas and President and Chief Executive Officer of Novartis Pharmaceutical Corporation. Prior to joining Novartis, Mr. Costa worked at Johnson & Johnson for 30 years, where he served as President of Janssen Pharmaceutica, Executive Vice President, Global Franchise Development, and was a member of Johnson & Johnson's Group Operating Committee. Mr. Costa has held various sales and marketing positions and has more than 20 years of general management experience, having launched 10 pharmaceutical products in various therapeutic areas in the U.S. market. He was elected to Amylin's Board at the Company's Annual Meeting of Stockholders on May 27, 2009.
"Our unanimous decision to name Paulo as Chairman reflects the Board's confidence in his leadership abilities," said James R. Gavin III, M.D., Ph.D., Director and Chair of Amylin's Corporate Governance Committee. "Paulo brings a fresh perspective to all aspects of Amylin's business at this important time for the Company, and his expertise regarding operational and commercial activities will be invaluable as we prepare for the launch of exenatide once weekly. We continue to position Amylin to compete and win in the diabetes and obesity markets. On behalf of the entire Board of Directors, we look forward to working with Paulo in his new leadership role."
"It is with great honor and pleasure that I accept the position of Amylin's Chair
|SOURCE Amylin Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved